BPA
ABBV icon

Beacon Pointe Advisors’s AbbVie ABBV Stock Holding History

Beacon Pointe Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,700
Closed -$625K – 1505
2025
Q3 		$625K Buy
+2,700
New +$550K 0.01% 934

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Beacon Pointe Advisors's ABBV Position: Q1 2026 in Review

Beacon Pointe Advisors increased its AbbVie (ABBV) stake by 31% in Q1 2026, buying an estimated $10.6M and bringing the position to 200,691 shares worth $43.6M. The position accounts for 0.23% of the portfolio, ranked #96.

Beacon Pointe Advisors first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Beacon Pointe Advisors held 200,691 shares of AbbVie worth $43.6M as of Q1 2026.
  • Beacon Pointe Advisors bought 47,749 AbbVie shares in Q1 2026, an estimated $10.6M.
  • AbbVie made up 0.23% of Beacon Pointe Advisors's portfolio in Q1 2026, its #96 holding.
  • Beacon Pointe Advisors first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.